Bioheart, Inc. , a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease announces that it has entered into an agreement with Invitrx Therapeutics to license their adipose derived stem cell products.
http://www.biospace.com/news_story.aspx?StoryID=309425&full=1
http://www.biospace.com/news_story.aspx?StoryID=309425&full=1
No comments:
Post a Comment